Graves’ ophthalmopathy in patients treated with radioiodine 131-I
2011
Background : Radioiodine treatment of hyperthyroidism in Graves’ disease patients may cause or aggravate the course of ophthalmopathy
(GO). We evaluated the activity and severity of ophthalmopathy in patients who acquired GO following radioiodine therapy.
Material and methods : Between 2003 and 2005, 763 Graves’ disease patients (50.9% of the total number of 1,500 patients referred to our
Department) were treated with radioiodine 131-I. This treatment was only offered to patients with NOSPECS score Results : In 39 patients who developed GO after 131-I treatment, median values of hTRAb and NOSPECS score were 15.4 U/L (IQR = 22.9)
and 5.0 points (max = 8.0; min = 2.0), respectively, at the time of their GO onset. Patients were qualified for methylprednisolone pulse
therapy (8.0 g) and subsequent radiotherapy (20 Gy). Median concentration of hTRAb and NOSPECS score at one, six and 12 months
post-GO therapy were: 10.0 U/L (IQR = 21.6) and 4.0 (max = 6.0; min = 1.0); 7.5 U/L (IQR = 1.1) and 3.0 (max = 10.0; min = 0.0); 2.8 U/L
(IQR = 8.3) and 3.0 (max = 6.0; min = 0.0), respectively. A positive association between hTRAb and NOSPECS score was observed over
the control period. IL-6 and IL-2 concentration prior to and one month after treatment remained elevated.
Conclusions : Since 5% of our Graves’ disease patients developed severe GO following radioiodine treatment, an association between
radioiodine therapy and severe ophthalmopathy cannot be excluded. IL-6 and IL-2 concentrations remained elevated after glucocorticoid
therapy. (Pol J Endocrinol 2011; 62 (3): 214–219)
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
27
References
3
Citations
NaN
KQI